Photys Therapeutics, Inc., a proximity-based therapeutics company, entered a multi-year collaboration and license agreement with Novo Nordisk to develop proximity-based therapeutics for a cardiometabolic disease target. The collaboration combines Novo Nordisk’s expertise in cardiometabolic diseases with Photys’ PHICS (PHosphorylation Inducing Chimeric Small molecules) technology, which induces proximity between a kinase and a target of interest to phosphorylate the target and thereby alter its b...